Fig. 3From: Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCTCumulative incidence curve for moderate-to-severe cGVHD (A) and Kaplan–Meier curve for GRFS (B) in CAEBV patients receiving PTCy after haplo-HSCTBack to article page